WANY
ARKG icon

Wealthspire Advisors (New York)’s ARK Genomic Revolution ETF ARKG Stock Holding History

Wealthspire Advisors (New York)’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,033
Closed -$28.7K – 1151
2025
Q3 		$28.7K Buy
+1,033
New +$26.1K ﹤0.01% 1488
2021
Q3 		– Sell
-2,363
Closed -$219K – 580
2021
Q2 		$219K Sell
2,363
-664
-22% -$56.5K 0.01% 342
2021
Q1 		$269K Buy
+3,027
New +$300K 0.01% 583

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Wealthspire Advisors (New York)'s ARKG Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2025, closing a stake of 1,033 shares — an estimated $28.7K sold.

Wealthspire Advisors (New York) first reported a position in ARKG in Q1 2021 and held it in 3 quarters. The position peaked at $269K in Q1 2021. 239 funds tracked by Wall St. Rank hold ARKG as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining ARK Genomic Revolution ETF position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 1,033 ARK Genomic Revolution ETF shares in Q4 2025, an estimated $28.7K.
  • Wealthspire Advisors (New York) first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 3 quarters.
  • Wealthspire Advisors (New York)'s ARK Genomic Revolution ETF position peaked at $269K in Q1 2021.
  • 239 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.